David B Volkin

Dr. Volkin joined KU's Department of Pharmaceutical Chemistry in 2010 after a 20-year industry career that included R&D senior director positions at Merck and Johnson & Johnson. He led formulation and analytical groups that brought dozens of candidates into human clinical trials, including five vaccines and three monoclonal antibodies approved by regulatory agencies. 

Dr. Volkin is co-founder of KU's Vaccine Analytics and Formulation Center (VAFC), which focuses on translation of novel vaccine/biotherapeutic candidates into clinical trials for use in low- and middle-income countries. The VAFC collaborates with a network of global partners including academia, biopharma companies, vaccine manufacturers, and non-profit organizations. His research focuses on understanding the changes in physicochemical properties that accompany the loss of biological activity, and developing new analytical techniques to monitor these changes at the molecular level. Dr. Volkin is co-inventor on 15 U.S. patents, and was awarded the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Award in Biotechnology in 2015.

Learn more about David Volkin on the Department of Pharmaceutical Chemistry website.